From content writing, to providing human-like responses in chatbots, and to even coding. Generative AI has made its potential known to the world with the introduction of ChatGPT.
But besides, did you know that generative AI can be used in the process of drug discovery as well?
Today we speak with Insilico Medicine, a clinical stage AI driven drug discovery company that is delivering breakthrough solutions to discover and develop medicines in areas such as cancer, immunity and ageing.
The company was selected by NVIDIA as one of the top 5 AI companies for its potential for social impact back in 2017. But how does it work, and what does a new drug discovery mean for the company?
Separately, Insilico Medicine had also signed a strategic research collaboration with pharmaceutical giant Sanofi in a deal worth up to US$1.2 billion last November. So, what is the status right now?
On Under the Radar, Drive Time’s finance presenter Chua Tian Tian posed these questions to Dr Alex Zhavoronkov, CEO of Insilico Medicine.

Market View: Asian markets mixed as investors mull extension of ceasefire between Lebanon and Israel for three weeks; Fed, ECB, BoJ, BoE rate decisions due next week; Meta, Microsoft plan cuts, buyouts that may affect 23,000 jobs; S-Reit earnings in focus; ST Engineering, Sheng Siong, CapitaLand Investment to watch
16:00

The Big Story: 72% say hawker culture is under threat from energy shocks, but can Singapore save it?
18:20

What’s Trending: Drake hid his upcoming album in ice... Also, would you be okay if AI replaced your favorite actors?
17:52